ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

DCT Adopts New Unsolicited Contract Review Procedures

May 21, 1976

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003

B-14 Trial: No Advantage To 10 Years Of Tamoxifen

May 25, 2001

In Brief: NCI-Litton Negations On Frederick continue; Staffs Not Worried About Possible GAO Probe

July 15, 1977

In Brief: Little Relation of Cancer Incidence To Known Carcinogens Except For Cigarettes, Holleb Says

July 14, 1978

Treatment Division Outlines Future Program Areas

January 24, 1975